Clinical Trials Logo

HER2-negative Breast Cancer clinical trials

View clinical trials related to HER2-negative Breast Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT01791478 Active, not recruiting - Clinical trials for Stage IV Breast Cancer

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Start date: April 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of the PI3K inhibitor BYL719 when given together with letrozole in treating patients with hormone receptor-positive metastatic breast cancer. The PI3K inhibitor BYL719 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving the PI3K inhibitor BYL719 together with letrozole may kill more tumor cells

NCT ID: NCT01527487 Active, not recruiting - Clinical trials for HER2 Negative Breast Cancer

Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

Start date: June 2012
Phase: Phase 2
Study type: Interventional

The investigators propose a randomized phase II study evaluating the pCR and toxicity profiles of combination eribulin/cyclophosphamide (ErC) and docetaxel /cyclophosphamide (TC) as neoadjuvant therapy for locally advanced HER2-negative breast cancer.

NCT ID: NCT01372579 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Start date: August 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving eribulin mesylate and carboplatin together before surgery works in treating patients with stage I-III triple-negative breast cancer. Drugs used in chemotherapy, such as eribulin mesylate and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.